- Home
- MBRX vs ADTX Comparison
MBRX vs ADTX Comparison
Compare MBRX & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- ADTX
- Stock Information
- Founded
- MBRX 2015
- ADTX 2017
- Country
- MBRX United States
- ADTX United States
- Employees
- MBRX N/A
- ADTX N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- MBRX Health Care
- ADTX Health Care
- Exchange
- MBRX Nasdaq
- ADTX Nasdaq
- Market Cap
- MBRX 4.4M
- ADTX 5.3M
- IPO Year
- MBRX 2016
- ADTX 2020
- Fundamental
- Price
- MBRX $0.84
- ADTX $5.58
- Analyst Decision
- MBRX Strong Buy
- ADTX
- Analyst Count
- MBRX 3
- ADTX 0
- Target Price
- MBRX $17.33
- ADTX N/A
- AVG Volume (30 Days)
- MBRX 651.2K
- ADTX 8.1M
- Earning Date
- MBRX 05-09-2025
- ADTX 05-19-2025
- Dividend Yield
- MBRX N/A
- ADTX N/A
- EPS Growth
- MBRX N/A
- ADTX N/A
- EPS
- MBRX N/A
- ADTX N/A
- Revenue
- MBRX N/A
- ADTX $133,985.00
- Revenue This Year
- MBRX N/A
- ADTX $95.61
- Revenue Next Year
- MBRX N/A
- ADTX $1,584.79
- P/E Ratio
- MBRX N/A
- ADTX N/A
- Revenue Growth
- MBRX N/A
- ADTX N/A
- 52 Week Low
- MBRX $0.40
- ADTX $4.11
- 52 Week High
- MBRX $5.91
- ADTX $35,000.00
- Technical
- Relative Strength Index (RSI)
- MBRX 36.19
- ADTX 35.33
- Support Level
- MBRX $0.92
- ADTX $4.17
- Resistance Level
- MBRX $1.04
- ADTX $7.69
- Average True Range (ATR)
- MBRX 0.10
- ADTX 1.71
- MACD
- MBRX -0.01
- ADTX 0.45
- Stochastic Oscillator
- MBRX 3.98
- ADTX 16.69
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.